133 related articles for article (PubMed ID: 7753047)
1. Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.
Barel M; Balbo M; Gauffre A; Frade R
Mol Immunol; 1995 Apr; 32(6):389-97. PubMed ID: 7753047
[TBL] [Abstract][Full Text] [Related]
2. EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein.
Frade R; Gauffre A; Hermann J; Barel M
J Immunol; 1992 Nov; 149(10):3232-8. PubMed ID: 1431101
[TBL] [Abstract][Full Text] [Related]
3. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes.
Barel M; Gauffre A; Lyamani F; Fiandino A; Hermann J; Frade R
J Immunol; 1991 Aug; 147(4):1286-91. PubMed ID: 1831222
[TBL] [Abstract][Full Text] [Related]
4. Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2.
Balbo M; Barel M; Bouillie S; Drane P; Cassinat B; Frade R
Mol Immunol; 1995 Nov; 32(16):1295-8. PubMed ID: 8559153
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.
Barel M; Fiandino A; Lyamani F; Frade R
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10054-8. PubMed ID: 2557614
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways.
Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R
Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
8. Nuclear localization of the Epstein-Barr virus/C3d receptor (CR2) in the human Burkitt B lymphoma cell, Raji.
Gauffre A; Viron A; Barel M; Hermann J; Puvion E; Frade R
Mol Immunol; 1992 Sep; 29(9):1113-20. PubMed ID: 1323059
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction.
Molina H; Brenner C; Jacobi S; Gorka J; Carel JC; Kinoshita T; Holers VM
J Biol Chem; 1991 Jul; 266(19):12173-9. PubMed ID: 1712014
[TBL] [Abstract][Full Text] [Related]
10. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Epstein-Barr virus/C3d receptor (EBV/C3dR or CR2) and nuclear p120 ribonucleoprotein phosphorylation by specific EBV/C3dR ligands in subcellular fractions of the human B lymphoma cell line, Raji.
Delcayre AX; Fiandino A; Lyamani F; Barel M; Frade R
Biochem Biophys Res Commun; 1989 Mar; 159(3):1213-20. PubMed ID: 2539145
[TBL] [Abstract][Full Text] [Related]
12. gp140, the EBV/C3d receptor (CR2) of human B lymphocytes, is involved in cell-free phosphorylation of p120, a nuclear ribonucleoprotein.
Delcayre AX; Fiandino A; Barel M; Frade R
Eur J Immunol; 1987 Dec; 17(12):1827-33. PubMed ID: 2446881
[TBL] [Abstract][Full Text] [Related]
13. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
14. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
Weis JJ; Toothaker LE; Smith JA; Weis JH; Fearon DT
J Exp Med; 1988 Mar; 167(3):1047-66. PubMed ID: 2832506
[TBL] [Abstract][Full Text] [Related]
15. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.
Martin DR; Yuryev A; Kalli KR; Fearon DT; Ahearn JM
J Exp Med; 1991 Dec; 174(6):1299-311. PubMed ID: 1660522
[TBL] [Abstract][Full Text] [Related]
16. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
17. Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ; Fearon DT; Klickstein LB; Wong WW; Richards SA; de Bruyn Kops A; Smith JA; Weis JH
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5639-43. PubMed ID: 3016712
[TBL] [Abstract][Full Text] [Related]
18. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
[TBL] [Abstract][Full Text] [Related]
19. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
